ABBV - AbbVie Inc.
89.60 -0.54 (-0.60%)
After hours: 5:19PM EST
| Previous Close | 88.31 |
| Open | 87.63 |
| Bid | 88.51 x 1300 |
| Ask | 90.25 x 1000 |
| Day's Range | 85.96 - 90.29 |
| 52 Week Range | 77.50 - 125.86 |
| Volume | 10,365,687 |
| Avg. Volume | 5,942,210 |
| Market Cap | 135.59B |
| Beta (3Y Monthly) | 1.73 |
| PE Ratio (TTM) | 22.37 |
| EPS (TTM) | 4.03 |
| Earnings Date | Jan 24, 2019 - Jan 28, 2019 |
| Forward Dividend & Yield | 4.28 (4.82%) |
| Ex-Dividend Date | 2019-01-14 |
| 1y Target Est | 100.58 |
- ACCESSWIRE•4 hours ago
ABBVIE LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 in AbbVie, Inc. to Contact the Firm
NEW YORK, NY / ACCESSWIRE / November 15, 2018 / Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in AbbVie, Inc. ("AbbVie" or the "Company") (ABBV) of the November 20, 2018 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you invested in AbbVie stock or options between October 25, 2013 and September 18, 2018 and would like to discuss your legal rights, click here: www.faruqilaw.com/ABBV.There is no cost or obligation to you.
Market Realist•6 hours agoUnderstanding Clovis Oncology’s Gross Margin Trend
For 2018 and 2019, Clovis Oncology (CLVS) is expected to generate revenues of $88.79 million and $165.13 million, respectively, compared to its revenue of $55.51 million in 2017.
Market Realist•6 hours agoExploring Clovis Oncology’s Operational Performance
Clovis Oncology (CLVS) incurred selling, general, and administrative expenses of $42.49 million in the third quarter compared to $35.01 million in the third quarter of 2017. This increase was due to higher commercialization activities for Rubraca and preparation for its expected launch in Europe.
- Benzinga•12 hours ago
The Daily Biotech Pulse: FDA Nod For Mallinckrodt's Pain Drug, AbbVie-Neurocrine Report Positive Elagolix Results
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 14) Vapotherm, Inc. (NYSE: VAPO )(listed following its IPO) ...
- ACCESSWIRE•yesterday
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AbbVie Inc. of Class Action Lawsuit and Upcoming Deadline – ABBV
NEW YORK, NY / ACCESSWIRE / November 14, 2018 / Pomerantz LLP announces that a class action lawsuit has been filed against AbbVie Inc. (''AbbVie'' or the ''Company'') (ABBV) and certain of its officers. The class action, filed in United States District Court, Northern District of Illinois, and index under 18-cv-06790, is on behalf of a class consisting of all persons and entities other than Defendants who purchased or otherwise acquired the publicly traded securities of AbbVie between October 25, 2013 and September 18, 2018, both dates inclusive (the ''Class Period''). Plaintiff seeks to recover compensable damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the ''Exchange Act'') and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- Zacks•yesterday
AbbVie (ABBV) Gains As Market Dips: What You Should Know
AbbVie (ABBV) closed at $88.31 in the latest trading session, marking a +0.1% move from the prior day.
- PR Newswire•yesterday
AbbVie Presents Positive Phase 3 Data Demonstrating Investigational Elagolix Reduces Heavy Menstrual Bleeding in Women with Uterine Fibroids at 2018 AAGL Global Congress
NORTH CHICAGO, Ill., Nov. 14, 2018 /PRNewswire/ -- AbbVie (ABBV), a research-based global biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. (NBIX), today presented for the first time additional results from two replicate pivotal Phase 3 clinical trials (ELARIS UF-1 (M12-815) and ELARIS UF-2 (M12-817)) evaluating the efficacy and safety of elagolix in women with uterine fibroids. These results were presented at the 47th American Association of Gynecologic Laparoscopists (AAGL) Global Congress on Minimally Invasive Gynecology in Las Vegas, NV. At the final month of the six-month treatment period, results demonstrated that elagolix (300 mg twice daily), in combination with low-dose hormone (add-back) therapy (estradiol 1.0 mg / norethindrone acetate 0.5 mg), reduced heavy menstrual bleeding associated with uterine fibroids compared to placebo.
- GlobeNewswire•yesterday
CLASS ACTION UPDATE for ABBV, CHGG and HTHT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, Nov. 14, 2018 -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies..
- Zacks•yesterday
AbbVie's HCV Drug Mavyret Succeeds in Label Expansion Study
AbbVie's (ABBV) Mavyret demonstrates high virologic cure rates in a study evaluating it for an expanded patient population.
- ACCESSWIRE•yesterday
6-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / November 14, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against AbbVie Inc. ("AbbVie" or "the Company") (NYSE: ABBV) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between October 25, 2013 and September 18, 2018, inclusive (the "Class Period"), are encouraged to contact the firm before November 20, 2018.
- GlobeNewswire•yesterday
November 20th AbbVie Deadline: Bernstein Liebhard LLP Reminds Investors of the Important Upcoming Deadline in the Shareholder Class Action Lawsuit Against AbbVie Inc. - ABBV
Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the important November 20, 2018 lead plaintiff deadline in the shareholder class action lawsuit against AbbVie Inc. (“AbbVie” or the “Company”) (ABBV). The lawsuit seeks to recover damages on behalf of those who purchased the securities of AbbVie between October 25, 2013 and September 18, 2018, both dates inclusive (the “Class Period”). If you purchased AbbVie securities, and/or would like to discuss your legal rights and options, please visit AbbVie Shareholder Class Action Lawsuit or contact Daniel Sadeh toll free at (877) 779-1414 or dsadeh@bernlieb.com.
- ACCESSWIRE•yesterday
DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against AbbVie Inc. (ABBV) & Lead Plaintiff Deadline - November 20, 2018
NEW YORK, NY / ACCESSWIRE / November 14, 2018 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against AbbVie Inc. ("AbbVie" or the "Company") ...
- Zacks•yesterday
The Zacks Analyst Blog Highlights: Berkshire Hathaway, AbbVie, Booking, HCA and Kimberly-Clark
The Zacks Analyst Blog Highlights: Berkshire Hathaway, AbbVie, Booking, HCA and Kimberly-Clark
- PR Newswire•2 days ago
AbbVie's MAVYRET™ (glecaprevir/pibrentasvir) Shows High Virologic Cure* Rates in Treatment-Naïve Hepatitis C Patients with Compensated Cirrhosis
NORTH CHICAGO, Ill., Nov. 13, 2018 /PRNewswire/ -- AbbVie (ABBV), a research-based global biopharmaceutical company, today announced new data for its pan-genotypic chronic hepatitis C virus (HCV) treatment, MAVYRET™ (glecaprevir/pibrentasvir), in treatment-naïve patients with compensated cirrhosis.
- PR Newswire•2 days ago
AbbVie to Present at the Evercore ISI Conference
NORTH CHICAGO, Ill. , Nov. 13, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the Evercore ISI HealthConX Conference on Tuesday, November ...
- Motley Fool•3 days ago
Better Buy: AbbVie Inc. vs. GlaxoSmithKline PLC
Which stock wins in a matchup between these two big drugmakers?
- GlobeNewswire•3 days ago
SHAREHOLDER ALERT: APOG COCP ABBV COST HTHT SFIX CWH OZK NKTR SYF: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
NEW YORK, Nov. 12, 2018 -- The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a.
- GlobeNewswire•3 days ago
INVESTOR REMINDER NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against AbbVie Inc. (“AbbVie” or “the Company”) (NYSE: ABBV) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.
Market Realist•3 days agoMost Analysts Are Bullish on Nektar Stock
In November 2018, of the total ten analysts covering Nektar Therapeutics (NKTR), eight analysts have given the stock a “buy” or higher rating, and two analysts have given it a “hold” rating. The mean rating for Nektar Therapeutics stock is 1.8 with a target price of $88.5, implying an upside potential of 160.1% over Nektar Therapeutics’ trading price of $34.03 on November 10.
- Motley Fool•3 days ago
Why AbbVie's Stock Cratered in October
AbbVie's stock hit bargain-basement territory last month. Here's why.
- GlobeNewswire•4 days ago
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of OPK, ABBV, MGTI, HAS and CPB
NEW YORK, Nov. 11, 2018 -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a.
- GlobeNewswire•6 days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AbbVie Inc. of Class Action Lawsuit and Upcoming Deadline – ABBV
Pomerantz LLP announces that a class action lawsuit has been filed against AbbVie Inc. (“AbbVie” or the “Company”) (NYSE: ABBV) and certain of its officers. The class action, filed in United States District Court, Northern District of Illinois, and index under 18-cv-06790, is on behalf of a class consisting of all persons and entities other than Defendants who purchased or otherwise acquired the publicly traded securities of AbbVie between October 25, 2013 and September 18, 2018, both dates inclusive (the “Class Period”). Plaintiff seeks to recover compensable damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- PR Newswire•6 days ago
Hagens Berman Reminds AbbVie (NYSE: ABBV) Investors of Ongoing Investigation of AbbVie's Humira Sales Practices
SAN FRANCISCO , Nov. 9, 2018 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP reminds investors in AbbVie Inc. (NYSE: ABBV) of the Firm's ongoing investigation of AbbVie's Humira sales practices. If you ...
- Market Realist•6 days ago
Assessing GW Pharmaceuticals’ Year-to-Date Performance
GW Pharmaceuticals (GWPH) is a developer of plant-derived cannabinoid therapeutics. GW Pharmaceuticals reported EPS of -$1.26 on revenue of $3.46 million in the third quarter, reflecting a 10.2% year-over-year revenue rise in the quarter.
- Zacks•6 days ago
Momenta (MNTA) Reports Narrower-Than-Expected Loss in Q3
Momenta (MNTA) posts narrower-than-expected loss in the third quarter, while revenues fall short of estimates.
